tiprankstipranks
CSL’s sparsentan did not achieve primary endpoint in glomerulosclerosis
The Fly

CSL’s sparsentan did not achieve primary endpoint in glomerulosclerosis

CSL announced topline primary efficacy results from the pivotal Phase 3 DUPLEX Study of sparsentan, a Dual Endothelin Angiotensin Receptor Antagonist – DEARA -, in focal segmental glomerulosclerosis – FSGS – from its partner Travere Therapeutics. At the end of the 108-week double-blind period, sparsentan was observed to have a 0.3 mL/min/1.73m2 per year favorable difference on eGFR total slope and a 0.9 mL/min/1.73m2 per year favorable difference on eGFR chronic slope compared to the active control irbesartan, which was not statistically significant. After 108 weeks of treatment, sparsentan achieved a mean reduction in proteinuria from baseline of 50%, compared to 32% for irbesartan. Results from the two-year analysis demonstrated that sparsentan was well-tolerated and has shown a comparable safety profile to irbesartan. The secondary, topline exploratory and hard endpoints in the study trended favorably for sparsentan. A preliminary review of the safety results through 108 weeks of treatment indicate sparsentan has been generally well-tolerated and the overall safety profile in the study to date has been generally consistent between treatment groups. Travere Therapeutics intends to complete a full evaluation of the data from the DUPLEX Study and work with study investigators on future presentations and publication of the results at an upcoming medical meeting and/or in a peer-reviewed publication.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on CSLLY:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles